Compare Stocks: KYMR, RAPP, SNY, and VERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$127.57 +0.3%	$117.14	$62.13 ▼ $142.92	$10.86B	2.04	975,533 shs	808,724 shs
RAPP Rapport Therapeutics	$26.15 +1.2%	$31.93	$22.06 ▼ $52.93	$1.53B	1.4	1.64 million shs	315,634 shs
SNY Sanofi	$48.37 -0.2%	$42.68	$39.07 ▼ $52.67	$117.49B	0.31	4.66 million shs	1.68 million shs
VERA Vera Therapeutics	$28.10 -3.2%	$31.11	$26.38 ▼ $56.05	$2.09B	1.07	1.56 million shs	1.01 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	+0.31%	-3.16%	+19.41%	+8.67%	+100.80%
RAPP Rapport Therapeutics	+1.16%	+7.00%	-7.70%	-44.85%	+3.89%
SNY Sanofi	-0.19%	+2.83%	+21.62%	+10.64%	-6.84%
VERA Vera Therapeutics	-3.24%	-5.64%	+5.09%	-11.16%	-9.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$127.57 +0.3%	$117.14	$62.13 ▼ $142.92	$10.86B	2.04	975,533 shs	808,724 shs
RAPP Rapport Therapeutics	$26.15 +1.2%	$31.93	$22.06 ▼ $52.93	$1.53B	1.4	1.64 million shs	315,634 shs
SNY Sanofi	$48.37 -0.2%	$42.68	$39.07 ▼ $52.67	$117.49B	0.31	4.66 million shs	1.68 million shs
VERA Vera Therapeutics	$28.10 -3.2%	$31.11	$26.38 ▼ $56.05	$2.09B	1.07	1.56 million shs	1.01 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	+0.31%	-3.16%	+19.41%	+8.67%	+100.80%
RAPP Rapport Therapeutics	+1.16%	+7.00%	-7.70%	-44.85%	+3.89%
SNY Sanofi	-0.19%	+2.83%	+21.62%	+10.64%	-6.84%
VERA Vera Therapeutics	-3.24%	-5.64%	+5.09%	-11.16%	-9.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYMR Kymera Therapeutics	2.89	Moderate Buy	$139.16	9.09% Upside
RAPP Rapport Therapeutics	2.93	Moderate Buy	$64.50	146.65% Upside
SNY Sanofi	2.48	Hold	$53.00	9.57% Upside
VERA Vera Therapeutics	2.80	Moderate Buy	$74.93	166.65% Upside

Current Analyst Ratings Breakdown

Latest KYMR, RAPP, SNY, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/9/2026	SNY Sanofi	BNP Paribas Exane Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Outperform	$57.00
11/6/2026	VERA Vera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$87.00
11/6/2026	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$76.00 ➝ $66.00
11/6/2026	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$34.00 ➝ $29.00
11/6/2026	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$90.00 ➝ $75.00
11/5/2026	RAPP Rapport Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$50.00 ➝ $47.00
11/5/2026	RAPP Rapport Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$71.00 ➝ $64.00
11/5/2026	RAPP Rapport Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$70.00 ➝ $66.00
11/4/2026	RAPP Rapport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$73.00
11/2/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C-)
11/2/2026	KYMR Kymera Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$139.00 ➝ $170.00

(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYMR Kymera Therapeutics	$39.21M	277.75	N/A	N/A	$18.91 per share	6.75
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$6.60 per share	N/A
SNY Sanofi	$49.35B	2.38	$7.05 per share	6.86	$34.77 per share	1.39
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$4.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYMR Kymera Therapeutics	-$311.35M	-$3.62	N/A	N/A	N/A	-285.33%	-22.39%	-20.48%	N/A
RAPP Rapport Therapeutics	-$111.48M	-$3.17	N/A	N/A	N/A	N/A	-34.00%	-31.89%	N/A
SNY Sanofi	$8.84B	$2.02	23.95	8.86	1.33	8.70%	15.16%	8.48%	N/A
VERA Vera Therapeutics	-$299.61M	-$5.90	N/A	N/A	N/A	N/A	-90.03%	-70.54%	N/A

Latest KYMR, RAPP, SNY, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	VERA Vera Therapeutics	-$1.62	-$1.30	+$0.32	-$1.30	$3.42 million	$10.28 million
11/4/2026	Q3 2026	RAPP Rapport Therapeutics	-$1.20	-$0.84	+$0.36	-$0.84	$0.01 million	N/A
10/30/2026	Q3 2026	SNY Sanofi	$1.56	$2.04	+$0.48	$1.43	$14.30 billion	$17.25 billion
10/29/2026	Q3 2026	KYMR Kymera Therapeutics	-$1.26	-$1.32	-$0.06	-$1.32	$3.28 million	$1.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.76	3.64%	+6.46%	87.13%	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYMR Kymera Therapeutics	N/A	11.13	11.13
RAPP Rapport Therapeutics	N/A	20.07	20.07
SNY Sanofi	0.20	1.12	0.27
VERA Vera Therapeutics	0.23	7.91	10.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYMR Kymera Therapeutics	N/A
RAPP Rapport Therapeutics	N/A
SNY Sanofi	14.03%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
KYMR Kymera Therapeutics	15.98%
RAPP Rapport Therapeutics	12.48%
SNY Sanofi	1.00%
VERA Vera Therapeutics	15.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYMR Kymera Therapeutics	285	85.37 million	71.73 million	Optionable
RAPP Rapport Therapeutics	84	59.28 million	51.88 million	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
VERA Vera Therapeutics	362	72.06 million	60.61 million	Optionable

KYMR, RAPP, SNY, and VERA Headlines

Recent News About These Companies

J.P. Morgan Remains a Buy on Vera Therapeutics (VERA)

1 minutes ago | theglobeandmail.com

Vera Therapeutics stock: Q3 revenue beats estimates by USD 6.88 million

November 12 at 10:58 PM | ad-hoc-news.deA

HC Wainwright Lifts Earnings Estimates for Vera Therapeutics

November 12 at 1:28 AM | americanbankingnews.com

HC Wainwright Has Strong Forecast for VERA FY2026 Earnings

November 10, 2026 | marketbeat.com

Vera Therapeutics, Inc. $VERA Shares Bought by Pictet Asset Management Holding SA

November 10, 2026 | marketbeat.com

Vera Therapeutics, Inc. $VERA Shares Sold by CenterBook Partners LP

November 10, 2026 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 6, 2026

November 9, 2026 | biospace.comB

Vera Therapeutics, Inc. $VERA Stock Acquired by Candriam S.C.A.

November 9, 2026 | marketbeat.com

Vera Therapeutics (VERA) Receives a Hold from Wedbush

November 8, 2026 | theglobeandmail.com

Vera Therapeutics (NASDAQ:VERA) Upgraded at Wall Street Zen

November 7, 2026 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 6, 2026 | globenewswire.com

Vera Therapeutics Q3 Earnings Call Highlights

November 6, 2026 | marketbeat.com

Vera Therapeutics (VERA) Stock Looks Above Fair Value After A 148% Run

November 6, 2026 | finance.yahoo.com

Vera Therapeutics (NASDAQ:VERA) Stock Gets Price Target Trim from HC Wainwright

November 6, 2026 | marketbeat.com

Vera Therapeutics (VERA) Q3 2026 Earnings Call Transcript

November 6, 2026 | finance.yahoo.com

Vera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 6, 2026 | marketscreener.comM

Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

November 6, 2026 | finance.yahoo.com

Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript

November 5, 2026 | seekingalpha.com

Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates

November 5, 2026 | zacks.com

Vera Therapeutics (NASDAQ:VERA) Releases Quarterly Earnings Results, Beats Expectations By $0.32 EPS

November 5, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Shares Break Above Fifty Day Moving Average - Should You Sell?

November 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KYMR, RAPP, SNY, and VERA Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

$127.57 +0.40 (+0.31%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$127.61 +0.04 (+0.03%)

As of 11/13/2026 07:59 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Rapport Therapeutics NASDAQ:RAPP

$26.15 +0.30 (+1.16%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$25.75 -0.40 (-1.53%)

As of 11/13/2026 07:30 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Sanofi NASDAQ:SNY

$48.37 -0.09 (-0.19%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$48.28 -0.09 (-0.18%)

As of 11/13/2026 07:52 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Vera Therapeutics NASDAQ:VERA

$28.10 -0.94 (-3.24%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$28.11 +0.01 (+0.04%)

As of 11/13/2026 07:33 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYMR, RAPP, SNY, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYMR, RAPP, SNY, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYMR, RAPP, SNY, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYMR, RAPP, SNY, and VERA Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

Rapport Therapeutics NASDAQ:RAPP

Sanofi NASDAQ:SNY

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYMR, RAPP, SNY, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYMR, RAPP, SNY, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYMR, RAPP, SNY, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYMR, RAPP, SNY, and VERA Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

Rapport Therapeutics NASDAQ:RAPP

Sanofi NASDAQ:SNY

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools